Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Interactions: Implications for Cardiovascular and Infectious Disease Research

Study Background and Research Question

The renin–angiotensin system (RAS) orchestrates blood pressure regulation and vascular homeostasis via a cascade of enzymatically generated peptides. Among these, angiotensin II and its fragments are well-characterized vasoconstrictor peptides, mediating blood pressure elevation and aldosterone release stimulation. Parallel to this, the COVID-19 pandemic has illuminated the role of angiotensin-converting enzyme 2 (ACE2) as the main entry receptor for SARS-CoV-2, with additional receptors such as neuropilin-1 (NRP1) and AXL modulating viral tropism, especially in tissues with low ACE2 expression. The reference study by Oliveira et al. addresses the novel hypothesis that endogenous angiotensin peptides directly influence the binding affinity of the SARS-CoV-2 spike protein to its cellular receptors, particularly AXL, thereby impacting viral infectivity and pathogenesis.

Key Innovation from the Reference Study

The central innovation of this study lies in systematically dissecting the modulatory effects of a spectrum of angiotensin-derived peptides—including both C- and N-terminal truncations—on the interaction between the SARS-CoV-2 spike protein and its primary host receptors. Unlike prior research, which predominantly focused on ACE2–spike interactions, Oliveira et al. demonstrate that shorter angiotensin peptide fragments, especially those with N-terminal deletions, robustly enhance spike–AXL binding. This marks a substantial extension of the known interface between the RAS and viral host cell entry, offering a mechanistic rationale for the observed cardiovascular complications in COVID-19 and pointing to new therapeutic targets within the renin–angiotensin signaling pathway.

Methods and Experimental Design Insights

The research team employed antibody-based quantitative binding assays to measure the impact of various angiotensin peptides and their modified analogs on spike protein attachment to AXL, ACE2, and NRP1. The experimental design included both full-length and truncated peptides: angiotensin I (1–10), angiotensin II (1–8), angiotensin (1–7), angiotensin (1–6), as well as N-terminally cleaved variants like angiotensin III (2–8), angiotensin IV (3–8), and angiotensin (2–7). Additionally, site-specific amino acid substitutions and post-translational modifications (e.g., tyrosine phosphorylation) were introduced to probe structure–function relationships.

• Binding assays were performed with recombinant spike protein and immobilized receptor molecules to quantify peptide-dependent modulation.
• Peptide concentrations and incubation conditions were optimized to reflect physiologically relevant ranges.
• Comparative assays across AXL, ACE2, and NRP1 allowed for receptor-specific assessment of peptide effects.

Protocol Parameters

• Peptide dosing: Angiotensin peptides (including (2–7) and (3–8)) were typically tested at micromolar concentrations aligned with reported plasma ranges and relevant to in vitro receptor binding models (reference study).
• Binding assessment: Quantitative ELISA-style assays with anti-spike protein detection were used to measure the fold-change in receptor binding in the presence or absence of peptide fragments.
• Receptor specificity: Parallel testing with ACE2, NRP1, and AXL as immobilized targets ensured precise attribution of peptide effects.
• Peptide modification analysis: Amino acid substitutions (e.g., Val for Tyr at position 4) and phosphorylation states were included to delineate critical residues for spike–receptor modulation.

Core Findings and Why They Matter

The study demonstrated that while full-length angiotensin I (1–10) did not impact spike–AXL binding, angiotensin II (1–8) and its shorter C-terminal truncations (1–7, 1–6) significantly increased spike–AXL interaction, generally doubling binding affinity. More strikingly, N-terminal truncations—specifically angiotensin III (2–8), angiotensin IV (3–8), and angiotensin (2–7)—yielded even greater enhancement, with angiotensin IV (3–8) leading to a 2.7-fold increase in binding. Modifications to the tyrosine residue at position 4 (either by substitution or phosphorylation) further amplified this effect, implicating specific sequence motifs in the peptide–receptor interplay. Notably, angiotensin IV also promoted spike protein binding to ACE2 and NRP1, indicating a broader role for these fragments in modulating viral entry pathways.

These results highlight a previously unrecognized intersection between blood pressure regulation research and infectious disease pathogenesis: endogenous RAS peptides can directly modulate virus–host interactions, potentially contributing to disease severity and clinical variability in COVID-19. This mechanistic insight provides a new lens for interpreting the cardiovascular manifestations observed in SARS-CoV-2 infections and underscores the need to consider RAS peptide profiles in both basic and translational research.

Comparison with Existing Internal Articles

Several internal resources, such as "Angiotensin 1/2 (2-7) Peptide: Next-Gen Protocols in Blood Pressure Research", emphasize the critical utility of the Angiotensin 1/2 (2-7) peptide in dissecting blood pressure regulation and the renin-angiotensin signaling pathway. These articles predominantly focus on cardiovascular research, detailing the advantages of using high-purity, well-characterized ARG-VAL-TYR-ILE-HIS-PRO peptides for reproducible results in vasoconstriction and aldosterone release studies. For example, one review highlights how the Angiotensin 1/2 (2-7) fragment enables nuanced interrogation of blood pressure and RAS dynamics.

Oliveira et al.'s findings extend these internal workflows by revealing that the same peptide fragments studied for cardiovascular endpoints also play a direct role in viral spike protein–receptor interactions, particularly with AXL. This connection forms a methodological bridge between cardiovascular and infectious disease research, validating the use of Angiotensin 1/2 (2-7) for cross-domain studies. Internal protocols can thus be adapted to include viral receptor binding assays alongside traditional vascular endpoints, leveraging the peptide’s robust solubility and purity as reported in both the literature and product information.

Limitations and Transferability

Despite its innovative approach, the reference study is primarily limited to in vitro receptor–ligand binding models, which, while mechanistically informative, do not fully recapitulate the complexity of in vivo viral infection or systemic RAS dynamics. The peptide concentrations required for significant modulation in vitro may not directly translate to physiological or pathophysiological conditions in patients. Furthermore, the study does not address downstream signaling consequences of enhanced spike–AXL binding or the long-term effects on host cell function.

Transferability to clinical or animal models will require careful validation of peptide dosing, temporal dynamics, and tissue-specific expression of both RAS components and viral receptors. Nonetheless, the experimental framework offers a robust starting point for expanding cardiovascular peptide workflows into the study of infectious disease mechanisms.

Why this cross-domain matters, maturity, and limitations

The intersection between RAS peptide biology and viral host cell entry is of high research significance, as it illuminates a potential mechanism underlying the vascular complications frequently observed in COVID-19. The maturity of this cross-domain bridge is moderate: while in vitro evidence is strong, in vivo and clinical validation remain outstanding. Limitations include uncertainty regarding the systemic relevance of observed binding enhancements and the need for further exploration into downstream pathophysiological effects.

Research Support Resources

Researchers seeking to model the interplay between blood pressure regulation and viral entry mechanisms can benefit from using high-purity peptide tools. Angiotensin 1/2 (2-7) (SKU A1050) from APExBIO offers a well-characterized, high-solubility ARG-VAL-TYR-ILE-HIS-PRO peptide suitable for both classic RAS and emerging spike protein binding studies. Its validated solubility in aqueous and organic solvents and rigorous quality profile support reliable experimental design in cardiovascular and infectious disease research.